Hints and tips:
Related Topics
...But the vast majority of doctors Insys targeted were not oncologists....
...In April 2015, Roddy Boyd, a hedge-fund analyst-turned-investigative reporter in North Carolina, published an exposé, “Insys Therapeutics and the New ‘Killing It’” on his non-profit site, called The Southern...
...The opioid drugmaker Insys Therapeutics, whose products include the fentanyl-based spray Subsys, has filed for Chapter 11 bankruptcy in the wake of a $225m settlement with the US government....
...Judge Kevin Gross, who is overseeing the Insys bankruptcy case, will have to decide whether those cases are just about pursuing money — as Insys argues — or about ensuring the company obeys the rules....
...How should funds be allocated between vaccines, therapeutics and testing? To drive the global response forward in low- and middle-income countries we need at least €2bn....
...In total, eight Insys executives have been prosecuted....
...Insys said Mr Kapoor’s shares were being managed by an independent trust and would be until they are disposed. Mr Kapoor owns 63.2 per cent of Insys shares, worth about $194.6m....
...Insys, the maker of Subsys, a spray based on the very powerful opioid fentanyl, settled a case for $225m last month....
...The day before I met Goldin in London, John Kapoor, the co-founder of Insys Therapeutics, which manufactured a fentanyl oral spray marketed as Subsys, was found guilty, along with four other executives,...
...(FT) Taking the rap A conspiracy trial in the US was shown a rap video of salesmen from Insys Therapeutics exhorting greater sales of Subsys, an addictive painkiller....
...Insys Therapeutics has named current chief financial officer Andrew Long to lead the company, replacing its chief executive Saeed Motahari, as the company deals with ongoing legal costs related to its promotion...
...One is Insys Therapeutics, a US biotech that generates revenues from opioids but spends a fifth of its research budget on cannabinoid drugs....
...Here’s one to watch from the world of speculative US healthcare: Insys Pharmaceuticals....
...Nasdaq-listed Insys Therapeutics, whose drugs include a synthetic cannabidiol formulation, trades at 22 times forward earnings....
International Edition